secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2023-07-21T23:59:59+00:00
Accession:  0000950170-23-033755
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Evoke Pharma extension to Nov 20, 2023 to meet equity requirement
-------------------------------------------------------------------------------

- Nasdaq extended deadline to Nov 20, 2023 to regain minimum $2.5M stockholders' equity.
- Company had stockholders' equity of $2.1M as of Mar 31, 2023, below the $2.5M requirement.
- Evoke submitted compliance plan on July 7, 2023; extension requires public evidence of compliance.
- Failure to comply by 10-K filing for Dec 31, 2023 could result in delisting from Nasdaq Capital Market.
- Company may appeal any delisting determination to a Hearings Panel, but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023033755/0000950170-23-033755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023033755/evok-20230719.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer